GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The President told Molotov that he visualized the enforced disarmament of our enemies and, indeed, some of our friends after the war; that he thought that the United States, England, Russia and perhaps China should police the world and enforce disarmament by inspection. The President said that he visualized Germany, Italy, Japan, France, Czechoslovakia, Rumania and other nations would not be permitted to have military forces. He stated that other nations might join the first four mentioned after experience proved they could be trusted. Roosevelt and Molotov continued their discussion of the Four Policemen in a second meeting on June 1. Molotov informed the President that Stalin was willing to support Roosevelt's plans for maintaining postwar peace through the Four Policemen and enforced disarmament. Roosevelt also raised the issue of postwar decolonization. He suggested that former colonies should undergo a period of transition under the governance of an international trusteeship prior to their independence. China was brought in as a member of the Big Four and a future member of the Four Policemen. Roosevelt was in favor of recognizing China as a great power because he was certain that the Chinese would side with the Americans against the Soviets. He said to British Foreign Secretary Anthony Eden, "In any serious conflict of policy with Russia, [China] would undoubtedly line up on our side." As it was before the Chinese Civil War was won by the Communists, he did not mean the Communist China, but the Republic of China.
=== Prussian Blue === Prussian Blue, also known as Berlin Blue, Paris Blue, or Turnbull's Blue, is an inorganic pigment, produced in large quantities for both artistic purposes and textiles. It has the chemical formula FeIII4[FeII(CN)6]3. With a history dating back to the early 18th century, Prussian blue remains a popular artistic pigment. Studies of Prussian Blue lead to discoveries about hydrogen cyanide. It is an antidote for heavy metal poisoning, and is famed for being used to color the uniforms of the Prussian army in the 18th century.
Napoleon: A Life. Penguin. ISBN 978-0-698-17628-7. Ryan, A. N. (1953). "The Causes of the British Attack upon Copenhagen in 1807". The English Historical Review. 68 (266): 37–55. doi:10.1093/ehr/lxviii.cclxvi.37. ISSN 0013-8266. Schäfer, Anton (2002). Zeittafel der Rechtsgeschichte. Von den Anfängen über Rom bis 1919. Mit Schwerpunkt Österreich und zeitgenössischen Bezügen (in German) (3rd ed.). Edition Europa Verlag. ISBN 3-9500616-8-1. Schroeder, Paul W. (1994). The Transformation of European Politics, 1763–1848. Clarendon Press. ISBN 978-0-19-820654-5. Sherwig, John M. (1969). Guineas and Gunpowder: British Foreign Aid in the Wars with France, 1793–1815. Harvard University Press. ISBN 978-0-674-36775-3. Shlapentokh, Dmitry (1997). The French Revolution and the Russian Anti-Democratic Tradition: A Case of False Consciousness. Transaction Publishers. ISBN 978-1-4128-2397-5. Stoker, Donald; Schneid, Frederick C.; Blanton, Harold D. (2008). Conscription in the Napoleonic Era: A Revolution in Military Affairs?. Taylor & Francis. ISBN 978-0-203-67404-8. Sutherland, Donald M. G. (2008). The French Revolution and Empire: The Quest for a Civic Order. John Wiley & Sons. ISBN 978-0-470-75826-7. Tone, John Lawrence (1996). "Napoleon's uncongenial sea: Guerrilla warfare in Navarre during the Peninsular War, 1808–14". European History Quarterly. 26 (3): 355–382. doi:10.1177/026569149602600302. S2CID 144885121. Tone, John Lawrence (2010). "Partisan Warfare in Spain and Total War". In Chickering, Roger; Förster, Stig (eds.). War in an Age of Revolution, 1775–1815. Cambridge UP. p. 243.
The glutathione reductase is conserved between all kingdoms. In bacteria, yeasts, and animals, one glutathione reductase gene is found; however, in plant genomes, two GR genes are encoded. Drosophila and trypanosomes do not have any GR at all. In these organisms, glutathione reduction is performed by either the thioredoxin or the trypanothione system, respectively.
Sources: en.wikipedia.org
The group released several reports on these effects as a cover story, claiming that their ionospheric studies had been interfering with the other experiments at the RRS at Slough, and expressing their gratitude that the Air Ministry had granted them access to unused land at Orfordness to continue their efforts. Bowen continued increasing the voltage in the transmitter, starting with the 5000 volt maximum suggested by the Navy, but increasing in steps over several months to 12,000 V, which produced pulses of 200 kW. Arcing between the valves required the transmitter to be rebuilt with more room between them, while arcing on the antenna was solved by hanging copper balls from the dipole to reduce corona discharge. By June the system was working well, although Bainbridge-Bell proved to be so skeptical of success that Watt eventually returned him to the RRS and replaced him with Nick Carter. The Tizard Committee visited the site on 15 June to examine the team's progress. Watt secretly arranged for a Vickers Valentia to fly nearby, and years later insisted that he saw the echoes on the display, but no one else recalls seeing these. Watt decided not to return to the RRS with the rest of the Tizard group and stayed with the team for another day. With no changes made to the equipment, on 17 June the system was turned on and immediately provided returns from an object at 17 mi (27 km). After tracking it for some time, they watched it fly off to the south and disappear.
With a population of 84.7 million according to the 2023 German census, Germany is the most populous member state of the European Union, the second-most populous country in Europe after Russia, and the nineteenth-most populous country in the world. Its population density stands at 236 inhabitants per square kilometre (610 inhabitants/mi2). The fertility rate of 1.36 children born per woman (2024 estimates) is below the replacement rate of 2.1, but slightly above the EU average of 1.34. Since the 1970s, Germany's death rate has exceeded its birth rate. However, the country is witnessing increased birth and migration rates since the early 2010s. Germany has the fourth oldest population in the world, with an average age of 47.8 years.
== Clinical significance == A chyle fistula occurs when defect(s) of lymphatic vessel(s) result in leakage of lymphatic fluid, typically accumulating in the thoracic (pleural) or abdominal (peritoneal) cavities, leading to a chylous pleural effusion (chylothorax) or chylous ascites, respectively. Leakage of lymphatic fluid and decreased chyle volume result in the loss of fluid, electrolytes, proteins, and lymphocytes, leading to complications with nutrition, wound healing, and immunity. Diagnosis of a chyle fistula may be accomplished by analysis of pleural/peritoneal fluid. Identifying the source (localizing the lymphatic defect) is often challenging, but may be accomplished with lymphangiography, which is occasionally associated with a serendipitous therapeutic effect (resolution of the leak), thought to be secondary to a sclerosant effect of the lymphangiography contrast. Because of the extreme friability of the lymphatic vessels, direct repair of defects is impractical. Therefore, treatment of chyle fistulae relies upon either decreased production of lymphatic fluid to allow for healing of lymphatic defect(s) or permanent diversion of lymphatic fluid away from lymphatic defect(s). Decreased production of lymphatic fluid may be accomplished by dietary restriction (or complete replacement of oral intake with total parenteral nutrition), as well as by the medications octreotide (a synthetic analogue of the hormone somatostatin) and orlistat (a lipase inhibitor that decreases absorption of dietary fats).
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.